[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353799-105":59,"doc-detail-353799-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","t-cell-receptorengineered-t-cells-targeting-the-tp53-r248q-neoantigen-elicit-antitumor-effects-in-human-cancer-models","T cell receptor–engineered T cells targeting the TP53 R248Q neoantigen elicit antitumor effects in human cancer models","","T cell receptor–engineered T cells were used to target the recurrent TP53R248Q neoantigen presented by HLA-A*11:01. The study identified an immunogenic neoantigen from the TP53R248Q mutation and isolated a cognate TP53R248Q-reactive TCR with no clear cross-reactivity toward wild-type TP53 or other TP53 mutants at the same codon. TP53R248Q TCR-T cells showed selective cytotoxicity against tumor cells expressing both TP53R248Q and HLA-A*11:01 in vitro, and demonstrated significant antitumor activity in a patient-derived xenograft model.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/t-cell-receptorengineered-t-cells-targeting-the-tp53-r248q-neoantigen-elicit-antitumor-effects-in-human-cancer-models/353799/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/t-cell-receptorengineered-t-cells-targeting-the-tp53-r248q-neoantigen-elicit-antitumor-effects-in-human-cancer-models/353799.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What neoantigen and HLA allele are targeted in this study?","Question",{"text":112,"@type":113},"The study targets the TP53R248Q neoantigen presented by the prevalent HLA-A*11:01 allele.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How specific is the identified TP53R248Q-reactive TCR?",{"text":117,"@type":113},"The isolated TCR specifically recognizes the TP53R248Q mutation and shows no discernible cross-activity with wild-type TP53 or other TP53 mutants at the same codon position.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports antitumor activity of TP53R248Q TCR-T cells?",{"text":121,"@type":113},"TP53R248Q TCR-T cells displayed selective cytotoxicity against tumor cells expressing both TP53R248Q and HLA-A*11:01 in vitro and produced significant antitumor activity in a patient-derived xenograft model.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353799,1790167377,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","The Journal of Clinical Investigation RESEAR CH ARTICLE  \nT cell receptor–engineered T cells targeting the TP53 R248Q neoantigen elicit antitumor effects in human cancer models  \nLianghua Shen,1,2 Ziyu Chen,1,2 Jian Xu,1,2 Qiaomei He,1 Changmeng Zhang,1 Xiao Zhou,1 Xiaodan Ding,1 Jinan Fang,1 Fanlin Li,1  \nMing Jiao,1 Yuqin Yang,1 Baoxia Dong,1 Liping Wan,1 Xueying Ding,2 Yan Zheng,3 Jingyi Zhou,4 Chijian Zuo,5 Tian Min,6 Ming Zhu,6 Bin Ma,6 Yuhua Wan,7 Qiufang Guo,7 Hua Zhang,7 Jian Hua,7 Pengran Wang,1,2 Qi Li,4 Jiang Long,3 Xianmin Song,1,2 and Yan Zhang1,2  \n1Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2Engineering Technology Research Center of Cell Therapy and Clinical Translation, Science and Technology Committee of Shanghai Municipality, Shanghai, China. 3Department of Pancreatic Surgery, Shanghai General Hospital, and 4Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 5Suzhou CureMed Biopharma Technology Co. Ltd., Suzhou, China. 6KuaiXu Biotechnologies Co. Ltd., Shanghai, China. 7SPH Biotherapeutics (Shanghai) Co. Ltd., Shanghai, China.  \nMalignant tumors with TP53 mutations exhibit poor therapeutic outcomes and high recurrence rates. T cell receptor–based (TCR-based) T cell therapy shows great promise for targeting intracellular cancer neoantigens. However, the immunogenic potential of TP53 hotspot mutations remains poorly characterized. Here, we identified an immunogenic neoantigen derived from the recurrent TP53R248Q mutation, presented by the prevalent HLA-A*11:01 allele. Additionally, we isolated a TP53R248Qreactive TCR that specifically recognized the TP53R248Q mutation without any discernible cross-activity with cognate WT TP53 or other TP53 mutants at the same codon position. Functional characterization revealed that TP53R248Q TCR-T cells exhibited selective cytotoxicity against tumor cells expressing both the TP53R248Q mutation and HLA-A*11:01 in vitro. Importantly, the adoptive transfer of TP53R248Q TCR-T cells exhibited significant antitumor activity in a clinically relevant patient-derived xenograft model engrafted with TP53R248Q/HLA-A*11:01–positive human tumor tissues. Collectively, our study validates the immunogenicity of the TP53R248Q hotspot mutation and provides a TCR with high therapeutic potential for the development of T cell therapies targeting TP53R248Q/HLA-A*11:01–positive cancers.  \nIntroduction  \nTP53 is the most frequently mutated tumor suppressor gene in over 50% of human cancers (1, 2) . TP53 mutations confer substantial growth advantages to cancer cells and correlate strongly with therapeutic resistance and poor prognoses. Approximately 90% of TP53 mutations across virtually all cancer subtypes are missense mutations, predominantly clustered at amino acid sites R175, G245, R248, R249, R273, R282, and Y220 (3, 4) . Such substitutions induce either thermodynamic destabilization of the TP53’s tertiary structure or alter DNA-binding specificity, thereby abrogating its tumor-suppressive functions through either structural destabilization or functional inactivation of the DNA-binding domains. Despite decades of intensive drug discovery efforts targeting mutant TP53, including pharmacological reactivators designed to restore wild-type conformation and transcriptional  \nConflict of interest: LS, PW, XD, JX, LM, Y Zhang, and XS are inventors of a Chinese patent covering the TP53R248Q TCR described herein, which was licensed to Shanghai General Hospital in February 2025 (CN118772260B) .  \nCopyright: © 2026, Shen et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.  \nSubmitted: June 10, 2025; Accepted: January 8, 2026; Published: January 13, 2026.  \nReference information: J Clin Invest. 2026;136(5):e196613 .  \n[https://doi.org/10.1172/JCI196613](https://doi.org/10.1172/JCI196613) .  \nactivity, ","cbCaibxYA3AWgjed","https://ap.wps.com/l/cbCaibxYA3AWgjed","pdf",9579747,18,"English","# Introduction\n## Background on TP53 mutations and neoantigens\n## Rationale for TCR-T therapy targeting public neoantigens","[{\"question\":\"What neoantigen and HLA allele are targeted in this study?\",\"answer\":\"The study targets the TP53R248Q neoantigen presented by the prevalent HLA-A*11:01 allele.\"},{\"question\":\"How specific is the identified TP53R248Q-reactive TCR?\",\"answer\":\"The isolated TCR specifically recognizes the TP53R248Q mutation and shows no discernible cross-activity with wild-type TP53 or other TP53 mutants at the same codon position.\"},{\"question\":\"What evidence supports antitumor activity of TP53R248Q TCR-T cells?\",\"answer\":\"TP53R248Q TCR-T cells displayed selective cytotoxicity against tumor cells expressing both TP53R248Q and HLA-A*11:01 in vitro and produced significant antitumor activity in a patient-derived xenograft model.\"}]","T cell receptor–engineered T cells targeting the TP53 R248Q neoantigen elicit antitumor effects in human cancer models | PDF",1790107300,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56afb251c22cd5f79d6dc08f7effa544.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de9cbe83e35a54777578c402f8c7607f.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6a1cd1305cfa5abe474fcaafe83595d.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/507765e2169c2fbc9403a363d35e083b.webp",980,1311]